PDCD1 and hepatocellular carcinoma: Taken together, and as shown in Table 4, current comparative data indicate that the addition of PD-1/PD-L1 inhibitors to radiotherapy does not appear to significantly elevate the risk of hepatotoxicity in patients with HCC.